Levetiracetam (Keppra ®)
|The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
|NS, D5W, or LR
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]
|[Prescribed dose] [100ml] [ 15 minutes]
(Product with particulate matter or discoloration should not be used.)
Stability / Miscellaneous
Indications: KEPPRA injection is indicated as adjunctive therapy in the treatment of partial onset seizures in ADULTS with epilepsy. KEPPRA injection is an alternative for patients when oral administration is temporarily not feasible.
Dosage: KEPPRA injection is for intravenous use only and must be diluted prior to administration. Treatment should be initiated with a daily dose of 1000 mg/day, given as twice-daily dosing (500 mg BID). Additional dosing increments may be given (1000 mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000 mg. Doses greater than 3000 mg/day have been used in open label studies with KEPPRA tablets for periods of 6 months and longer. There is no evidence that doses greater than 3000 mg/day confer additional benefit.
Note: dosage adjustments are necessary in patients with impaired renal function.
Replacement Therapy: When switching from oral KEPPRA, the initial total daily intravenous dosage of KEPPRA should be equivalent to the total daily dosage and frequency of oral KEPPRA . Any unused portion of the KEPPRA injection vial contents should be discarded.
Source: [package insert]